New drug LM-24C5 enters human testing for advanced cancers

NCT ID NCT06187402

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 23 times

Summary

This study tests a new drug called LM-24C5 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 49 adults will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Indiana University Melvan and Bren Simon Cancer Center

    NOT_YET_RECRUITING

    Indianapolis, Indiana, 46202, United States

    Contact

  • Mary Crowley Cancer Research Center

    NOT_YET_RECRUITING

    Dallas, Texas, 75230, United States

    Contact

  • Ocala Oncology

    RECRUITING

    Ocala, Florida, 34474, United States

    Contact

  • The Christ Hospital

    NOT_YET_RECRUITING

    Cincinnati, Ohio, 45219, United States

    Contact

  • University of Southern California (USC) - Norris Comprehensive Cancer Center

    NOT_YET_RECRUITING

    Los Angeles, California, 90089, United States

    Contact

  • Virginia Cancer Specialists, P.C.

    NOT_YET_RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact

Conditions

Explore the condition pages connected to this study.